A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Amgen and Zai Lab have agreed to run a global clinical trial combining two DLL3 targeted therapies for small cell lung cancer ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen Inc. (NASDAQ:AMGN) is included among the 13 NASDAQ Stocks with Highest Dividends. On April 10, Morgan Stanley analyst ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

Zai Lab (ZLAB) stock jumps as the company announces a global clinical trial collaboration with Amgen (AMGN). Read more here.

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

CUMBERLAND – Advanced Placement Biology students at Cumberland High School conducted a hands-on lab experiment using ...

SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products ...

Amgen has performed decently but it’s best returns are still ahead.

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...